Hypertrophic cardiomyopathy: trials for referral
103 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
103 trials shown
No phase8 sites
Not yet recruitingUnited States
NCT07806149
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
National Heart, Lung, and Blood Institute (NHLBI)
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingUnited States
NCT07867288
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 40 sites
Not yet recruiting
NCT07897500
Dapagliflozin in Patients With Non-Obstructive Hypertrophic Cardiomyopathy: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Yonsei University
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 260 sites
RecruitingAustria, Belgium, Germany, Spain, France, United Kingdom
NCT07023614
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 2/3143 sites
By invitation onlyArgentina, Australia, Brazil, Canada, Czechia, Germany
NCT04848506
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Cytokinetics
Registry updated 13 Oct 2026
Registry record: ClinicalTrials.govNo phase8 sites
Not yet recruitingUnited Kingdom
NCT07865364
Coronary Sinus Reducer Objective Impact on SymptoMs, Ischaemia and miCrovascular Resistance in Non-obstructive Hypertrophic CardioMyopathy
Imperial College London
Registry updated 8 Oct 2026
Registry record: ClinicalTrials.govPhase 26 sites
RecruitingGermany, United Kingdom, Italy, United States
NCT06092034
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
Rocket Pharmaceuticals Inc.
Registry updated 6 Oct 2026
Registry record: ClinicalTrials.govPhase 33 sites
RecruitingUnited States
NCT07755904
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Braveheart Bio, Inc.
Registry updated 2 Oct 2026
Registry record: ClinicalTrials.govPhase 41 site
By invitation onlyChina
NCT07103655
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
Second Affiliated Hospital, Zhejiang University, School of Medicine
Registry updated 15 Sept 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07817186
Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT
Carelon Research
Registry updated 14 Sept 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingChina
NCT07815301
Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy
First Affiliated Hospital of Wenzhou Medical University
Registry updated 11 Sept 2026
Registry record: ClinicalTrials.govPhase 40 sites
Not yet recruiting
NCT07807384
Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Second Affiliated Hospital of Nanchang University
Registry updated 8 Sept 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07721025
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics
Registry updated 2 Sept 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07675668
Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy
Amckaus PTY LTD.
Registry updated 30 Jun 2026
Registry record: ClinicalTrials.govPhase 317 sites
RecruitingFrance
NCT07202897
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Rennes University Hospital
Registry updated 12 Jun 2026
Registry record: ClinicalTrials.govPhase 42 sites
RecruitingUnited States
NCT07600177
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Oregon Health and Science University
Registry updated 20 May 2026
Registry record: ClinicalTrials.govPhase 23 sites
RecruitingChina
NCT07367724
Ademetionine in Obstructive Hypertrophic Cardiomyopathy
China National Center for Cardiovascular Diseases
Registry updated 20 Mar 2026
Registry record: ClinicalTrials.govPhase 1/210 sites
RecruitingUnited States
NCT05836259
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
Tenaya Therapeutics
Registry updated 19 Mar 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
RecruitingUnited States
NCT06433050
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
University of Pennsylvania
Registry updated 11 Feb 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingRussia
NCT07372196
Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy
Meshalkin Research Institute of Pathology of Circulation
Registry updated 28 Jan 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingChina
NCT07294495
Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR
Shanghai East Hospital
Registry updated 19 Dec 2025
Registry record: ClinicalTrials.govNo phase2 sites
RecruitingChina
NCT07006493
REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy
SuZhou Sinus Medical Technologies Co.,Ltd
Registry updated 15 Dec 2025
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT07021963
A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd.
Registry updated 10 Sept 2025
Registry record: ClinicalTrials.govPhase 44 sites
RecruitingDenmark
NCT05569382
Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy
Morten Steen Kvistholm Jensen
Registry updated 20 Mar 2025
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT06873828
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
Yonsei University
Registry updated 13 Mar 2025
Registry record: ClinicalTrials.govNo phase0 sites
Not yet recruiting
NCT06856265
Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Shanghai Chest Hospital
Registry updated 4 Mar 2025
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingChina
NCT06794710
Early Identification and Treatment of Rare Cardiomyopathy Cohorts
RenJi Hospital
Registry updated 27 Jan 2025
Registry record: ClinicalTrials.govPhase 41 site
RecruitingSouth Korea
NCT06580717
ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy
Yonsei University
Registry updated 8 Nov 2024
Registry record: ClinicalTrials.govPhase 21 site
RecruitingPoland
NCT06555237
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
Medical University of Warsaw
Registry updated 15 Aug 2024
Registry record: ClinicalTrials.govNo phase1 site
RecruitingCanada
NCT04464655
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
McGill University Health Centre/Research Institute of the McGill University Health Centre
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States22 open trials
- China19 open trials
- United Kingdom14 open trials
- Germany10 open trials
- Italy8 open trials
- France8 open trials
- Austria6 open trials
- Poland5 open trials
- Netherlands4 open trials
- Spain4 open trials
- Canada4 open trials
- Portugal3 open trials
- Belgium3 open trials
- Russia3 open trials
- Brazil2 open trials
- Denmark2 open trials
- Czechia2 open trials
- South Korea2 open trials
- Sweden2 open trials
- Japan2 open trials
- Greece1 open trial
- Hungary1 open trial
- Australia1 open trial
- Israel1 open trial
- Puerto Rico1 open trial
- Argentina1 open trial
- Türkiye1 open trial
- Taiwan1 open trial
- Egypt1 open trial
- Singapore1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
1 trial · 15 publications · ROR
Hospital of the University of Pennsylvania
Philadelphia, United States
7 trials · 11 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Closed for recruitment
NCT06412666 · Phase 2/3 · Canada, Spain, United Kingdom, Ireland, Italy, Japan
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT06081894 · Phase 3 · Argentina, Australia, Brazil, Canada, China, Germany
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 2/3
NCT04848506 · Phase 2/3 · Argentina, Australia, Brazil, Canada, Czechia, Germany
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
NCT04848506 · Phase 2/3 · Argentina, Australia, Brazil, Canada, Czechia, Germany
Source: ClinicalTrials.govPhase changed: Phase 3 → Phase 2/3
NCT03723655 · Phase 2/3 · Belgium, Czechia, Germany, Denmark, Spain, France
Source: ClinicalTrials.govOpened for recruitment
NCT06412666 · Phase 2/3 · Canada, Spain, United Kingdom, Ireland, Italy, Japan
Source: ClinicalTrials.govNew in the registry
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
NCT04464655 · No phase · Canada
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 3Ended 2 Oct 2026
Completed250 participants
2024-517643-31-00
Does the use of empagliflozin improve exercise capacity in patients with hypertrophic cardiomyopathy.
No phaseEnded 17 Sept 2026
Stopped early17 participants
NCT07103057
VIZ ACCESS HCM - Multi-Site Registry
Reason given: Sponsor company opted to shift design into single center investigator initiated study focus.
No phaseEnded 1 Sept 2026
Stopped early380 participants
NCT04080492
A Cardiac Disease Quality of Life Study
Reason given: Enrollment goal not met
No phaseEnded 1 Aug 2026
No phaseEnded 24 Feb 2026
Stopped early36 participants
NCT07155434
ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access
Reason given: The sponsor terminated the study following an internal review of program priorities.
Phase 2/3Ended 16 Jan 2026
Completed314 participants
NCT03723655
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: An integrated analysis of phase 3 clinical trials. · American heart journal, 2027
No phaseEnded 7 Jan 2026
Completed5 participants
NCT05938283
Pilot Study of Hypertrophic Cardiomyopathy & Implantable Cardioverter Defibrillator Assessment: (Subcutaneous vs Transvenous)
No phaseEnded 31 Dec 2025
Completed23 participants
NCT06540183
Percutaneous Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy in Children
Phase 3Ended 11 Dec 2025
Phase 2Ended 29 Nov 2025
Phase 2Ended 18 Nov 2025
Completed84 participants
NCT06816251
A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy
No phaseEnded 23 Oct 2025
Stopped early1 participant
NCT06775886
Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy
Reason given: PI left the institution. IRB study closure date of 11/12/2025. IRB approved closeout on 2/6/2026.
Phase 3Ended 20 Oct 2025
Completed282 participants
NCT05582395
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy
Phase 3Ended 20 Oct 2025
Completed40 participants
NCT06116968
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
Phase 4Ended 16 Sept 2025
Completed725 participants
2023-508743-43-00
Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy
Phase 1Ended 23 Jul 2025
Completed24 participants
NCT06775834
Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function
Phase 1Ended 3 Jul 2025
Completed7 participants
NCT03882437
Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B
No phaseEnded 30 Jun 2025
Completed222 participants
NCT07529938
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
No phaseEnded 2 Jun 2025
No phaseEnded 30 May 2025
Withdrawn before start0 participants
NCT04050579
OPIE in the Thin Interventricular Septum
Reason given: Study was determined to be focused on Quality Assurance (QA) and Quality Improvement (QI), rather than research, based on its primary purpose and activities. Study was closed prior to enrollment.
Show more
No phaseEnded 16 May 2025
Completed149 participants
NCT06181617
A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan
No phaseEnded 18 Apr 2025
Completed683 participants
NCT06549608
A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
Phase 3Ended 28 Mar 2025
Completed175 participants
NCT05767346
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
- Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. · Journal of the American College of Cardiology, 2026
- Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM. · JACC. Heart failure, 2026
- The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy. · Journal of cardiac failure, 2026
No phaseEnded 25 Mar 2025
Phase 2Ended 27 Feb 2025
No phaseEnded 21 Jan 2025
Completed1 participant
NCT04153162
Non-Invasive Radiation Ablation in Patients With Hypertrophic CardioMyopathy: NIRA-HOCM
No phaseEnded 31 Dec 2024
No phaseEnded 23 Dec 2024
Stopped early1 participant
NCT06269640
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study
Reason given: Clinical trials terminated early due to trial feasibility
No phaseEnded 19 Dec 2024
No phaseEnded 18 Sept 2024
Completed82 participants
NCT05646056
A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk
Phase 2Ended 30 Jul 2024
Completed154 participants
NCT04706429
The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
- Trientine for hypertrophic cardiomyopathy: a phase 2 trial. · European heart journal, 2026
Phase 3Ended 22 Jul 2024
Completed81 participants
NCT05174416
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
- Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study. · Cardiology and therapy, 2026
- Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: An integrated analysis of phase 3 clinical trials. · American heart journal, 2027
- Long-Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER-CN Study. · Journal of the American Heart Association, 2026
No phaseEnded 30 Jun 2024
No phaseEnded 21 Jun 2024
Phase 3Ended 20 May 2024
Completed112 participants
NCT04349072
A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
- Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: An integrated analysis of phase 3 clinical trials. · American heart journal, 2027
No phaseEnded 31 Mar 2024
Phase 1Ended 21 Mar 2024
Completed76 participants
NCT05879523
A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy
Phase 4Ended 15 Mar 2024
Completed105 participants
2022-502316-36-00
Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy
No phaseEnded Dec 2023
Phase 3Ended 18 Dec 2023
Completed282 participants
NCT05186818
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
- The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy. · Journal of cardiac failure, 2026
- Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. · Circulation. Heart failure, 2026
Not medical advice. fetched 10 Nov 2026